| Biotech Co.* | Pharma Co. (Country) | Product | Disclosed Funding (M) | Terms/Details (Date) |
| | ||||
| Aclara Bio- | Roche Applied | Arteas product | ND | Collaboration for the worldwide marketing and distribution of Aclara's Arteas product line (11/7) |
| Alkermes | Janssen | Risperdal | ND | Agreement provides for the expansion of Alkermes' manufacturing capacity for production of Risperdal (10/30) |
| Applied | AsiaGen | Tuberculosis diagnostics | ND | Manufacturing and marketing agreement for tuberculosis diagnostics using Applied Gene's Tessera Array Technology; Applied Gene will receive an up-front payment for the development; AsiaGen gains exclusive rights to market and manufacture the product in Asia (11/5) |
| Bresagen | ProGen | Bacteria containing equine growth hormone, somatotropin | ND | Manufacturing supply agreement to produce the bacteria that produces the hormone, which will be purified by BresaGen and formulated into EquiGen (9/26) |
| Bresagen | Image-Guided | Specialized catheter intended to be used for delivery of cells into the brain | ND | IGN will develop the catheter for BresaGen, which has an exclusive license to commercialize the device (9/26) |
| Cell Thera- | Natural Pharm- | Paclitaxel | ND | Supply agreement under which NPI will supply paclitaxel to CTI (10/23) |
| Connetics | Miza Pharma- | Luxiq and Olux foams | ND | Manufacturing and supply agreement for Luxiq and Olux targeted for the dermatology market; the agreement is for several years with a potential for renewal (9/21) |
| Dendreon | Gambro | Dendreon's therapeutic | ND | Gambro's U.S. network of clinics will serve as cell collection centers, and Gambro BCT's COBE Spectra Apheresis System will be used for the cell collection procedure; the collected cells serve as a raw material component in the production of Dendreon's cancer vaccines (10/23) |
| Dragon | Emcure | Recombinant erythropoietin | ND | Marketing and licensing agreement for the distribution of the drug in India and and throughout the South Asian subcontinent, as well as in markets in sub-Saharan Africa (11/5) |
| Forest Lab- | Lipha SA | Campral (acamprosate) | ND | Distribution, marketing, trademark license and supply agreement for the U.S. rights to Campral to treat alcohol addiction (10/23) |
| Genencor | The Procter | Protease enzymes | $600 | Five-year worldwide supply contract to provide protease enzymes for laundry and dish detergents; the agreement is estimated to be worth up to $600M in product revenues over the life of the contract (11/7) |
| InforMax | Amersham | InforMax desktop software products | ND | Agreement for the exclusive distribution of the products in Latin America (10/26) |
| Interneuron | J. Uriach | Dersalazine, a compound to treat inflammatory bowel disease | ND | Interneuron gains worldwide marketing rights to dersalazine, except in Spain; it will be responsible for clinical development, regulatory activities and commercialization; the agreement includes an up-front licensing payment, development milestones and royalty payments to Uriach (10/1) |
| Lorus Thera- | Faulding | Virulizin | ND | Seven-year distribution agreement in which Faulding will market and sell Virulizin, to treat malignant melanoma, in Mexico; Lorus will receive royalties and will be responsible for manufacturing; Faulding will share in any additional clinical costs (10/15) |
| Myriad | Fleury Lab- | BRACAnalysis, Colaris and Myriad's new Melaris predictive medicine products | ND | Collaboration is to market the products throughout Brazil (11/14) |
| Orchid Bio- | MiraiBio | SNPstream MT | ND | Multiyear marketing agreement for Orchid's SNPstream MT product; MiraiBio gained nonexclusive worldwide rights to market the genotyping consumables and software developed by Orchid; Orchid retains rights to distribute the system (10/8) |
| Proteome | Alpha | Alphalmager and FluorChem imaging systems | ND | Alpha Innotech will manufacture the imaging systems for incorporation with Proteome Systems' ProteomeIQ integrated proteomics platform (10/15) |
| Third Wave | Otsuka | Invader research products | ND | Marketing and distribution agreement under which Otsuka will distribute Invader research products in Japan and other countries in the Far East, Southeast Asia and the Middle East; Otsuka also will market and develop the product, as well as provide technical support (10/22) |
| Viragen Inc. | Tradeway | Multiferon | $255 | Tradeway will purchase $5M of Viragen's natural alpha interferon product to complete the regulatory process in Taiwan; upon approval, Tradeway will purchase an additional $250M of the drug in increments of $50M over a five-year period (10/31) |
| Visible | Bio- | TruGene HIV-1 Genotyping Test | ND | Agreement is to offer VGI's test to Bio-Reference customers treating patients with HIV infections; the companies will co-market and support the product in New York, New Jersey and greater Philadelphia, and provide patient education programs (9/25) |
| | ||||
NOTES | ||||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed, reported and/or available | ||||
| AMEX = American Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
